Investing.comDoubao · 实盘不做把握 6/10不做原因:风险收益比不佳
北京时间·🕒 发布 04:16:25·⟳ 抓取 04:17:07 +42s·⚡ 决策 10-09 04:25:20 +8m13s·18.9 天前
Guardant Health 的 Guardant360 CDx 获欧盟 CE 标志，作为乳腺癌伴随诊断配套阿斯利康 ETCAMAH
方向虽为正面，但这是同一药物继美、日后的第三地区、公司第31项伴随诊断的常规增量批准，未披露收入或测试量指引，相对222亿美元市值缺乏可量化的短期业绩弹性；盘后仅+0.6%且成交量极低，缺乏正期望，不构成可交易 edge。
📄 原文Investing.com↗ 原文
Guardant Health receives European approval for breast cancer test
By Investing.com Advertisement Advertisement Guardant Health receives European approval for breast cancer test Company…
不做 Guardant Health（GH.US）
同一药物继美、日后的第三地区、公司第31项伴随诊断的常规增量批准，无收入/测试量指引，相对222亿美元市值短期弹性低；盘后+0.6%且低量，缺乏正期望 edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Guardant360 CDx 获欧盟 CE 标志是产品线的渐进式地域扩张，非首次、非独占、无金额指引，对公司短期基本面影响有限；盘后市场反应平淡，风险收益不足，回避。
🔎 新鲜度:最早出现 2026-10-08 · 扩散 low · price-in 风险 low ↗
关键理由
- 事件方向正面，巩固 Guardant360 CDx 在乳腺癌伴随诊断的全球覆盖，但属同一药物的第三地区常规批准。
- 盘后股价仅+0.6%、成交量约1万股，市场本身未将其视为重大催化。
主要风险
- ETCAMAH 在欧盟渗透或 ESR1 检测需求若显著超预期，可能带来被低估的测试量拉动。
- 公司未盈利且近期波动大（10月6日单日-8.8%），题材情绪可能放大短期价格波动。
反向证据
- 做多前查反向 · 来源 web · 影响 weakens
行情显示公司未盈利(PE -49.9)、近5日-5.26%、10月6日单日-8.83%，股价高波动且处于回调，做多缺乏顺风；未见本次批准对应的具体业绩指引。
检索:GH Guardant Health recent guidance cut headwind breast cancer liquid biopsy competition
先例如何影响了这次决策
对本次决策的影响:因催化本身属低 materiality 的常规增量批准，先例不足以也无必要把它升级为可交易机会，最终回避。
方向:未构建可比先例面板
涨幅量级:缺乏同市场、同相位的伴随诊断地区扩展批准先例来校准幅度
形态:无法从先例判断见光死概率
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 12 ms
{"result": "search_processed_events:agent query=`guardant health european approval companion diagnostic esr1 astrazeneca | guardant health guardant360 cdx ce mark breast cancer etcamah camizestrant`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重 - stock_quote 成功 stock_tools HTTP · 139 ms
{
原文全文
展开原文 · 7,110 字
Guardant Health receives European approval for breast cancer test By Investing.com
Advertisement
Advertisement
Guardant Health receives European approval for breast cancer test
Company News
Published
Oct 08, 2026, 04:16 PM
Guardant Health receives European approval for breast cancer test
View all comments (0)
0
Guardant Health receives European approval for breast cancer test
View all comments (0)
0
© Reuters
In this article:
GH
-1.65%
PALO ALTO, Calif. -
Guardant Health
Inc. (
NASDAQ:GH
) announced today that its Guardant360 CDx test has received CE-marking under Europe’s in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic for breast cancer patients.
The approval allows the test to identify patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from treatment with ETCAMAH (camizestrant), AstraZeneca’s oral selective estrogen receptor degrader.
The test detects ESR1 mutations in tumors through a blood draw. The European approval follows prior regulatory approvals of Guardant360 CDx as a companion diagnostic for ETCAMAH in the United States and Japan, according to a press release statement.
"Guardant360 CDx offers molecular insights that can support informed treatment decisions for patients with advanced breast cancer," said Helmy Eltoukhy, Guardant Health chairman and co-CEO.
This marks the company’s 31st companion diagnostic approval and the third for ETCAMAH. Guardant360 CDx is a liquid biopsy test for comprehensive genomic profiling that detects multiple genomic alterations across solid tumors. The test is approved as a companion diagnostic for therapies in non-small cell lung cancer, breast cancer and colorectal cancer.
Guardant Health, founded in 2012, develops blood and tissue tests for cancer detection and treatment selection. The company is based in Palo Alto, California.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Guardant Health receives European approval for breast cancer test
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,274.70
+95.5
+0.19%
US 500
7,770.30
-31.4
-0.40%
Dow Jones
51,231.70
+51.83
+0.10%
S&P 500
7,764.51
-37.26
-0.48%
Nasdaq
27,193.34
-345.35
-1.25%
S&P 500 VIX
15.42
+0.34
+2.25%
Dollar Index
101.87
-0.060
-0.06%
Crude Oil WTI Futures
90.82
-0.67
-0.73%
Brent Oil Futures
103.53
-0.75
-0.72%
Natural Gas Futures
3.133
-0.037
-1.17%
Gold Futures
4,160.37
+3.37
+0.08%
Silver Futures
59.455
+0.035
+0.06%
Copper Futures
6.5625
-0.0075
-0.11%
US Soybeans Futures
1,286.50
-11.00
-0.85%
U.S. 10Y
5.223
-0.055
-1.04%
U.S. 30Y
5.602
-0.059
-1.04%
U.S. 5Y
4.985
-0.036
-0.72%
U.S. 3M
4.151
+0.010
+0.24%
US 10Y T-Note Futures
104.75
+0.27
+0.25%
Euro Bund Futures
121.20
+0.39
+0.32%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
340.42
+3.75
+1.11%
NVDA
230.48
-6.99
-2.94%
GOOGL
348.29
-2.21
-0.63%
TSLA
375.00
-2.81
-0.74%
AMZN
254.06
-5.86
-2.25%
NFLX
71.57
+1.87
+2.68%
META
720.89
-0.42
-0.06%
Advertisement
Most Popular Articles
News
Analysis
Oil cuts gains after Trump says will not attack Iran before U.S. midterm elections
By Investing.co
...
Oct 08, 2026
Nasdaq ends over 1% lower as tech stocks take a hit on OpenAI revenue report
By Investing.co
...
Oct 09, 2026
Citi names 5 top chip picks ahead of Q3 earnings
By Investing.co
...
Oct 08, 2026
Oracle and these 6 stocks are newest addition to Mizuho Top Picks list
By Investing.co
...
Oct 08, 2026
Why Citi says the Fed could be setting up for a dovish surprise
By Investing.co
...
Oct 08, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
Oil Tops $100 as Stocks Come Under Pressure - Dow’s 50,000 Level Now in Focus
By Fawad Razaqz
...
Oct 08, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
9 Fundamentally Strong Stocks to Watch as Q3 Earnings Get Underway
By David Wagner
Oct 08, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,035.85
-4.79%
25.61M
NVDA
230.48
-2.94%
109.06M
SNDK
1,609.46
-4.90%
8.97M
AMD
620.79
-3.88%
19.85M
INTC
107.13
-5.30%
104.63M
SPCX
160.57
-4.19%
65.12M
AAPL
340.42
+1.11%
30.25M
Name
Last
Chg. %
Vol.
CSGP
29.81
+8.01%
9.42M
GDDY
103.19
+6.15%
1.61M
CMG
32.65
+6.11%
63.69M
ACN
208.36
+5.96%
7.42M
IT
195.41
+5.19%
721.05K
CTSH
60.02
+5.17%
7.46M
EPAM
113.86
+5.11%
438.12K
Name
Last
Chg. %
Vol.
ALAB
346.90
-9.25%
5.28M
CRWV
81.58
-7.77%
41.30M
NBIS
219.71
-7.35%
21.10M
ARM
275.29
-6.48%
5.52M
GLW
152.83
-6.38%
7.94M
VST
156.14
-6.35%
10.58M
LITE
1,048.61
-5.62%
4.53M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,035.85
-4.79%
25.61M
NVDA
230.48
-2.94%
109.06M
SPCX
160.57
-4.19%
65.12M
APLD
23.850
+0.17%
54.59M
SNDK
1,609.46
-4.90%
8.97M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
Advertisement
Advertisement
Guardant Health receives European approval for breast cancer test
Company News
Published
Oct 08, 2026, 04:16 PM
Guardant Health receives European approval for breast cancer test
View all comments (0)
0
Guardant Health receives European approval for breast cancer test
View all comments (0)
0
© Reuters
In this article:
GH
-1.65%
PALO ALTO, Calif. -
Guardant Health
Inc. (
NASDAQ:GH
) announced today that its Guardant360 CDx test has received CE-marking under Europe’s in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic for breast cancer patients.
The approval allows the test to identify patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from treatment with ETCAMAH (camizestrant), AstraZeneca’s oral selective estrogen receptor degrader.
The test detects ESR1 mutations in tumors through a blood draw. The European approval follows prior regulatory approvals of Guardant360 CDx as a companion diagnostic for ETCAMAH in the United States and Japan, according to a press release statement.
"Guardant360 CDx offers molecular insights that can support informed treatment decisions for patients with advanced breast cancer," said Helmy Eltoukhy, Guardant Health chairman and co-CEO.
This marks the company’s 31st companion diagnostic approval and the third for ETCAMAH. Guardant360 CDx is a liquid biopsy test for comprehensive genomic profiling that detects multiple genomic alterations across solid tumors. The test is approved as a companion diagnostic for therapies in non-small cell lung cancer, breast cancer and colorectal cancer.
Guardant Health, founded in 2012, develops blood and tissue tests for cancer detection and treatment selection. The company is based in Palo Alto, California.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Guardant Health receives European approval for breast cancer test
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,274.70
+95.5
+0.19%
US 500
7,770.30
-31.4
-0.40%
Dow Jones
51,231.70
+51.83
+0.10%
S&P 500
7,764.51
-37.26
-0.48%
Nasdaq
27,193.34
-345.35
-1.25%
S&P 500 VIX
15.42
+0.34
+2.25%
Dollar Index
101.87
-0.060
-0.06%
Crude Oil WTI Futures
90.82
-0.67
-0.73%
Brent Oil Futures
103.53
-0.75
-0.72%
Natural Gas Futures
3.133
-0.037
-1.17%
Gold Futures
4,160.37
+3.37
+0.08%
Silver Futures
59.455
+0.035
+0.06%
Copper Futures
6.5625
-0.0075
-0.11%
US Soybeans Futures
1,286.50
-11.00
-0.85%
U.S. 10Y
5.223
-0.055
-1.04%
U.S. 30Y
5.602
-0.059
-1.04%
U.S. 5Y
4.985
-0.036
-0.72%
U.S. 3M
4.151
+0.010
+0.24%
US 10Y T-Note Futures
104.75
+0.27
+0.25%
Euro Bund Futures
121.20
+0.39
+0.32%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
340.42
+3.75
+1.11%
NVDA
230.48
-6.99
-2.94%
GOOGL
348.29
-2.21
-0.63%
TSLA
375.00
-2.81
-0.74%
AMZN
254.06
-5.86
-2.25%
NFLX
71.57
+1.87
+2.68%
META
720.89
-0.42
-0.06%
Advertisement
Most Popular Articles
News
Analysis
Oil cuts gains after Trump says will not attack Iran before U.S. midterm elections
By Investing.co
...
Oct 08, 2026
Nasdaq ends over 1% lower as tech stocks take a hit on OpenAI revenue report
By Investing.co
...
Oct 09, 2026
Citi names 5 top chip picks ahead of Q3 earnings
By Investing.co
...
Oct 08, 2026
Oracle and these 6 stocks are newest addition to Mizuho Top Picks list
By Investing.co
...
Oct 08, 2026
Why Citi says the Fed could be setting up for a dovish surprise
By Investing.co
...
Oct 08, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
Oil Tops $100 as Stocks Come Under Pressure - Dow’s 50,000 Level Now in Focus
By Fawad Razaqz
...
Oct 08, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
9 Fundamentally Strong Stocks to Watch as Q3 Earnings Get Underway
By David Wagner
Oct 08, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,035.85
-4.79%
25.61M
NVDA
230.48
-2.94%
109.06M
SNDK
1,609.46
-4.90%
8.97M
AMD
620.79
-3.88%
19.85M
INTC
107.13
-5.30%
104.63M
SPCX
160.57
-4.19%
65.12M
AAPL
340.42
+1.11%
30.25M
Name
Last
Chg. %
Vol.
CSGP
29.81
+8.01%
9.42M
GDDY
103.19
+6.15%
1.61M
CMG
32.65
+6.11%
63.69M
ACN
208.36
+5.96%
7.42M
IT
195.41
+5.19%
721.05K
CTSH
60.02
+5.17%
7.46M
EPAM
113.86
+5.11%
438.12K
Name
Last
Chg. %
Vol.
ALAB
346.90
-9.25%
5.28M
CRWV
81.58
-7.77%
41.30M
NBIS
219.71
-7.35%
21.10M
ARM
275.29
-6.48%
5.52M
GLW
152.83
-6.38%
7.94M
VST
156.14
-6.35%
10.58M
LITE
1,048.61
-5.62%
4.53M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,035.85
-4.79%
25.61M
NVDA
230.48
-2.94%
109.06M
SPCX
160.57
-4.19%
65.12M
APLD
23.850
+0.17%
54.59M
SNDK
1,609.46
-4.90%
8.97M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
d303279f69· 2026-10-09 04:25 · doubao / doubao-seed-evolving-latest-version · 策略包d5018cb8913f当前